ملخص البحث :
Chimeric Antigen Receptor (CAR) based therapies are becoming increasingly important in treating patients. CAR-T cells
have been shown to be highly efective in the treatment of hematological malignancies. However, harmful therapeutic barriers
have been identifed, such as the potential for graft-versus-host disease (GVHD), neurotoxicity, and cytokine release syndrome
(CRS). As a result, CAR NK-cell therapy is expected to be a new therapeutic option. NK cells act as cytotoxic lymphocytes,
supporting the innate immune response against autoimmune diseases and cancer cells by precisely detecting and eliminating
malignant cells. Genetic modifcation of these cells provides a dual approach to the treatment of AD and cancer. It can be used
through both CAR-independent and CAR-dependent mechanisms. The use of CAR-based cell therapies has been successful
in treating cancer patients, leading to further investigation of this innovative treatment for alternative diseases, including
AD. The complementary roles of CAR T and CAR NK cells have stimulated exploration in this area. Our study examines
the latest research on the therapeutic efectiveness of these cells in treating both cancer and ADs.
-
سنة النشر : 2024
-
تصنيف البحث : scopus
- تحميل